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RenalThe stimulation of mitochondrial biogenesis (MB) via cell surface G-protein coupled receptors is a prom-
ising strategy for cell repair and regeneration. Here we report the speciﬁcity and chemical rationale of a
panel of b2-adrenoceptor agonists with regards to MB. Using primary cultures of renal cells, a diverse
panel of b2-adrenoceptor agonists elicited three distinct phenotypes: full MB, partial MB, and non-MB.
Full MB compounds had efﬁcacy in the low nanomolar range and represent two chemical scaffolds con-
taining three distinct chemical clusters. Interestingly, the MB phenotype did not correlate with reported
receptor afﬁnity or chemical similarity. Chemical clusters were then subjected to pharmacophore mod-
eling creating two models with unique and distinct features, consisting of ﬁve conserved amongst full MB
compounds were identiﬁed. The two discrete pharmacophore models were coalesced into a consensus
pharmacophore with four unique features elucidating the spatial and chemical characteristics required
to stimulate MB.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.The regulation of cellular energy demand is complex and essen-
tial for the homeostasis of cellular processes and responses to cel-
lular stress.1,2 While mitochondria have a number of functions, the
synthesis of adenosine triphosphate (ATP) is critical to cellularac-
tivities. When mitochondria do not properly function, ATP deple-
tion occurs and redox imbalances result in oxidative stress that
can lead to cell death. Ischemic injuries are a primary cause of
mitochondrial dysfunction and include acute injuries to organs
such as the kidney, liver and heart, as well as stroke.3 Mitochon-
drial dysfunction is also associated with multiple chronic disease
states including Alzheimer disease and diabetes.4,5 Consequently,
the discovery of compounds that stimulate mitochondrial biogen-
esis (MB) may have vast therapeutic potential.
MB is the continuous process to form new mitochondria within
the cell. MB is necessary to maintain cellular homeostasis, and can
be induced during periods of cellular stress or injury. The recent
identiﬁcation of a few compounds that induce MB, havehighlighted
the process as an important therapeutic target. To study MB, a phe-notypic assay is of particular utility. Cellular O2 consumption rates
(OCR) reﬂect the functional activity of the mitochondria, and are
reﬂective of cellular health. We speciﬁcally determined MB by
measuring maximal OCR after the addition of the proton ionophore
carbonylcyanide p-triﬂuoromethoxyphenylhydrazone (FCCP).6
FCCP uncouples oxygen consumption from the production of ATP
resulting in maximal activity of the mitochondrial electron trans-
port chain. If a chemical induces MB, then the FCCP-uncoupled
OCR (FCCP-OCR) increases when compared to diluent controls.
We have validated this assay with compounds known to cause
MB.7,8 It should also be noted that the respiratory experiments
were conducted in primary culturesof rabbit renal proximal tubule
cells (RPTC) grown under improved culture conditions, which are
highly dependent on aerobic respiration and similar to that found
in vivo.7,8 Although FCCP-OCR is a one dimensional parameter it is
reﬂective of a complex process and ideal for identifying MB. Fur-
thermore, using primary cultures of RPTC have signiﬁcant scientiﬁc
and clinical relevance compared to similar assays in cell lines, due
to the reliance of RPTC on aerobic respiration.
The b2-AR represents a major and well-studied receptor respon-
sible for multiple phenotypes including smooth muscle relaxation,
increased cardiac chronotropy and ionotropy, increased insulin
and renin secretion, and glycogenolysis.9–12 At the molecular level
the renin secretion,and glycogenolysis2-AR is a classical G-protein
coupled receptor that couples to both Gsa and Gia, increasing the
Figure 1. Generalized chemotype of MB stimulating b2-AR agonists and similar compounds.
Figure 2. Representative b2-AR agonists and similar compounds induce concentration-responsive increases in FCCP-uncoupled OCR after 24 h. Values indicate a percent of
fold change relative to DMSO controls. Data is represented a mean ± SEM, N = 4.
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AR has been demonstrated but the effect of ligand chemotype is
still a major question.15–19 Using RPTC respirometry we showedthat the selective b2 agonist formoterol was a potent stimulator
of MB while the non-selective b2-AR agonist, isoproterenol, was
not. Using formoterol as a template we used Tanimoto coefﬁcient
Figure 3. Chemical clustering, pKd and MB activity of b2-AR agonists and similar
compounds. MAACS keyed chemical ﬁngerprints were used to cluster compounds
based on molecular similarity as measured by Tanimoto Coefﬁcient. Three major
clusters were identiﬁed and numbered within the chemogram. The MB heat map
indicates full (red), partial (yellow), and inactive (green) biogenic compounds as
determined by RPTC OCR. The pKd heat map indicates the reported afﬁnity for each
ligand to the b2-AR with high afﬁnity (red), intermediate (yellow), and low afﬁnity
(green). The chemogram was rendered using Dendroscope.41
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probe the LOPAC library. This method revealed that nisoxetine, a
structural congener of epinephrine or formoterol, caused MB and
we created an initialpharmacophore model with common chemi-
cal elements between formoterol and nisoxetine.15 In this study
we expand our work and investigated a panel of chemically diverse
but selective b2-AR agonists as well as tomoxetine and nisoxetine
in regards to their effects on MB.
To expand our understanding of b2-agonist-stimulated MB we
tested b2-AR agonists and similar ligands. RPTC were exposed to
increasing concentrations (10–3000 nM) of these compounds and
24 h later FCCP-OCR was determined.20,21 Chemical evaluation re-
vealed that fourteen compounds contain a phenethylamine core
common to many biogenic amine ligands that are b-AR speciﬁc
agonists (Fig 1). The OCR measurements were performed using a
Seahorse Bioscience XF-96 instrument according to the protocol
outlined in Beeson et al.21 Each experimental plate was treated
with vehicle controls (DMSO <0.5%), a positive control (SRT1720,
10 lM), blank controls, and the appropriate concentration of the
compound of interest. Based on preliminary studies the biogenic
threshold value was <1.15 for the mean ratio of: (chemical treat-
ment FCCP-OCR/vehicle control FCCP-OCR). This threshold is P1
S.D. above the historic mean for the vehicle control. From our anal-
ysis we identiﬁed nine compounds that increased FCCP-uncoupled
OCR compared to the vehicle control at 24 h (Fig. 2).
We began interrogating b2-AR agonist regulation of MB bytest-
ing the endogenous catecholamines, epinephrine and norepineph-
rine (Figs. 1 and 2). These compounds did not promote MB. A set of
three related ligands with greater selectivity for the b2-AR: isopro-
terenol, clenbuterol, and isoetharine also had no effect on MB. A
second set of four ligands (terbutaline, ritodrine, cyclopentylbuta-
nepharine, and metaproteranol) were very efﬁcacious at low con-
centrations but were not MB as concentrations increased (Fig. 2).
Five of the twelve compounds tested were very potent, had
Michaelis–Menten type concentration–response curves and in-
cluded fenoterol, formoterol, procaterol, nisoxetine and tomoxe-
tine (Fig. 2). Although the mechanism is still not full elucidated,
the MB effects of tomoxetine were blocked by the b2-AR antagonist
ICI-118,551.15 These data indicate that subtle manipulations of li-
gand structure can alter potency and efﬁcacy of MB mediated by
the b2-AR. The lack of MB with epinephrine and norepinephrine
also support that norepinephrine reuptake inhibitor activity is
not responsible for MB.
Next we analyzed the reported afﬁnities of the b2-AR agonists
for a correlation with MB. The panel we tested ranged in afﬁnity
(pKd) for the b2-AR from 9.3 to 5.4 at concentrations from 1 to
10,000 nM (Fig. 3). Unexpectedly, there was no strong correlation
between afﬁnity and MB efﬁcacy. Compounds with very weak
afﬁnity trended to having little efﬁcacy while compounds full MB
responses all had a pKd>7. However, compounds with very high
afﬁnity like ritodrine, clenbuterol, and CPB only gave a partial
MB response, regardless of concentration.
Due to the discrepancy in the ability of high afﬁnity and selec-
tive b2-AR ligands to stimulate MB, we interrogated the ligand
structure using chemical similarity clustering (Fig. 3). Modeling
and visualizations were performed using MOE Version 2011.10
(CCG). Compound similarity was measured and visualized using
the Tanimoto coefﬁcient metric based on MACCS structural keys
using ChemMine single linkage hierarchical clustering.22 Three
major clusters were identiﬁed. The largest cluster contained most
of the classical b2-AR agonists and the endogenous catecholamines.
Another cluster contained formoterol, fenoterol and ritodrine. A
third cluster segregatednisoxetine and tomoxetine. Again, there
was no strong correlation between chemical similarity andMB efﬁ-
cacy as all three clusters contained at least one compound that has
a robust MB efﬁcacy proﬁle (Fig. 3). These data reveal that there arevery subtle but discrete chemical changes required for promoting
MB. To probe these subtle chemical changes, we explored ligand
structure in 3D pharmacophoric space.
The cluster 1 and 2 compounds procaterol, formoterol and fen-
oterol were aligned by hand based on steric considerations.23 The
alignment was then reﬁned using ﬂexible alignment. The ﬁnal
pharmacophore model generated had 100% consensus features
with a maximum feature radius of 1.2 Å (Fig. 4B). Features F1–F5
represents thephenethylamine core found in many sympathomi-
metic compounds as well as the endogenous sympathetic agonists.
Given features F5 and F6 are present in all of the fully biogenic
cluster 1/2 compounds, these features occupy necessary space for
MB. However, because non-biogenic compounds (e.g., isoprotere-
nol) contain these features, they are not sufﬁcient for mitochon-
drial biogenesis. On the other hand, F7 is present in the non-
biogenic endogenous catecholamines but not in the cluster 3 com-
pounds, making it neither necessary nor sufﬁcient for mitochon-
drial biogenesis. Comparing ritodrine to formoterol and fenoterol
feature F6, represented by the R6 constituent, needs to contain a
propyl group to support MB (Figs. 1 and 4). Comparing procaterol
to CPB, terbutaline and metaproterenol there is a unique ring at
pharmacophore feature F7, represented by the R3 constituent,
and propane atR5 are required to support MB (Figs. 1 and 4).
Cluster 3 contained nisoxetine and tomoxetine, which are char-
acterized as norepinephrine reuptake inhibitors (NRIs) and repre-
sent non-classical but chemically similar compounds to b2-AR
agonists that stimulate MB. Nisoxetine and tomoxetine were
aligned in ﬁrst two and then three dimensions. As in cluster 1/2,
the ﬁnal pharmacophore model generated had 100% consensus
features with a maximum feature radius of 1.4 Å (Fig. 4D). Features
F1–F5 in this pharmacophore also represents the phenethylamine
core. However, unlike the cluster 1/2 pharmacophore, there were
no further hydrophobic substituents on the carbon alpha to the
nitrogen hydrogen bond donor group. This indicates that features
F8 and F9 (aromatic and hydrophobic acceptor, respectively),which
are absent from the cluster 1/2 pharmacophore, are sufﬁcient to
stimulate MB when coupled with the phenethylamine core. Com-
Figure 4. Pharmacophore modeling of phenethylamines. (A) Cluster 1/2: procaterol, formoterol and fenoterol. (B) Pharmacophore overlay of cluster 1 pharmacophore with
cluster 2 pharmacophore. Procaterol, formoterol and fenoterol were ﬂexibly aligned to superimposed chemical features. (C) Cluster 3: nisoxetine and tomoxetine. (D)
Pharmacophore model based on alignment of cluster 3. Nisoxetine and tomoxetine were ﬂexibly aligned to superimposed chemical features. E and F. Pharmacophore overlay
of cluster 1/2 pharmacophore with cluster 3 pharmacophore. (E) Overlay of 5 compounds with features from cluster 1/2 and cluster 3 pharmacophore models. (F) Consensus
features derived from both cluster models with consensus features labeled in black and MB speciﬁc features in brown. The connectivity path of the phenethylamine core is
depicted as a black line. F1 and F8 are aromatic, F2 and F9 are proton donors, F3, F5, and F6 are hydrophobic, F4 and F7 are protonacceptors.
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cated pharmacophore features F8 and F9, representing the R4 con-
stituent, minimally requires a methylphenol group to support MB
(Figs. 1 and 4).
We then determined potential overlap of cluster 1/2 and cluster
3 (Fig. 4E/F). The primary positioning parameter was the overlap of
corresponding features with hydrogen-bonding interactions. The
resulting similar feature volumes were merged into a consensus
feature to create a single larger volume that encompassed both
the discrete features for each model. Five features had both chem-
ical and spatial overlap. Three of the conserved features represent
the phenethylamine core and we found two more features con-
served between clusters 1/2 and cluster 3 compounds. This left
four discrete features (F6–F9) derived from the two primary
models.
These data indicate that all of the MB compounds share a por-
tion of a similar binding mode, but each cluster utilizes at least
two discrete interactions that are required outside of the pheneth-
ylamine core to support full MB. In the consensus pharmacophore
and consistent with the discrete models, F1–F5 represent thephenethylamine core. The hydrophobic feature F5 is present in
all clusters, but absent or minimal in the endogenous catechola-
mines, is therefore a necessary addition to the phenethylamine
core in stimulating MB. Of note, F7 is a donor feature in the meta
position to the ethanamine portion of the core and is unique to
the cluster 1/2 pharmacophore. Because it is not found in the other
clusters and is also present in non-biogenic compounds, it is nei-
ther necessary nor sufﬁcient forMB. However, it may play a role
in stabilizing receptor interactions of individual compounds to
generate a conformational change that induces MB. The presence
of the hydrophobic F6 may provide the necessary additional fea-
ture to stabilize a speciﬁc MB stimulating conﬁrmation. The com-
bined features of the phenyl F8 and donor F9 together are also
sufﬁcient to support MB. In both cases the addition of two features
is required to the canonical ﬁve features of the phenethylamine
core.
We tested 14 chemically similar compounds for their ability to
promote increases in RPTC OCR at low concentrations 24 h after
exposure. We observed there are three distinct OCR phenotypes
including full MB, partial MB, and non-MB activities amongst the
5380 Y. K. Peterson et al. / Bioorg. Med. Chem. Lett. 23 (2013) 5376–5381agonists and similar compounds. These compounds were parsed
into three major chemical clusters, two cluster-speciﬁc pharmaco-
phore models, and a consensus pharmacophore model. MB efﬁcacy
did not correlate withany particular chemical cluster using this ap-
proach nor reported pKd for the b2-AR (Fig. 3). We have rationally
expanded the chemical space available for MB to include two nor-
epinephrine/serotonin reuptake inhibitors (NRIs). NRIs represent a
vast chemical space, but nisoxetine and tomoxetine represent a
distinct and limited class of NRIs.5 Other NRIs lack the features
we describe here and found necessary for supporting b2-AR medi-
ated MB. Common features found in many other NRIs including tri-
cyclic systems (desipramine, mazindol, tandamine, ciclazindol) or
substituted indenes (amedalin, daledalin, talopram, and talsup-
ram) would not be supportive of MB, and are structurally more dis-
similar form the b2 type compounds we and others describe.
Ourinitial supposition was that the MB potential of the com-
pounds would correlate with their reported afﬁnity. Even though
most the compounds studied here are b2-AR selective and seven
of the partial and full compounds are efﬁcacious at 10–30 nM,
there appears to be no relationship between pKd and MB potential
(Fig. 3). Alternatively, other properties including duration of signal-
ing and receptor occupancy could explain the observed effect. It is
therefore interesting to note how dissimilar the absolute chemical
structures are between compounds like formoterol, procaterol and
tomoxetine are, but their 3D chemical features are nonetheless in
tight correlation in chemical space (Figs. 1 and 3 vs Fig. 4). The con-
sensus pharmacophore model derivedfrom the discrete pharmaco-
phore models allows for the precise spatial orientation of the
chemical moieties and revealed there are four discrete interactions
that govern MB.
The partial and non-biogenic compounds have classical archi-
tecture incorporating both ethanolamine and either catechol or
resorcinol moieties, while none of the full biogenics have a cate-
chol. From a chemistry perspective, isoetharine and procaterol
are bioisosteres of one another, with procaterol having a quinoline
system rather than a catechol. However, procaterol is strongly bio-
genic, while isoetharine is not, indicating that the space occupied
by the quinoline ring is also important for the MB phenotype. Fur-
thermore, CPB exhibits a partial biogenic response while differing
from isoetharine by only two carbons. This indicates that, in addi-
tion to the stronger hydrogen bond interactions with the receptor,
weaker hydrophobic interactions play an important role in differ-
entiatingphenotypic responses in the b2-AR. There were more po-
tential hydrophobic interactions in the full biogenics compared
to the other two classes of compounds.
The mechanisms and utility of b2-AR regulated MB are of great
interest. The regulation of adenylyl cyclases and cAMP by the b2-AR
are well studied and there is evidence in the literature to suggest
cAMP directly and indirectly regulates mitochondrial function by
activating diverse molecules like PKA and Epac that lead to PGC1a
activation.16,24–29 However, other b2-AR regulated pathways (i.e.,
Ca2+ and CamKKb or AMPK) may also be involved.30–33 Future stud-
ies are needed to elucidate the speciﬁc b2-AR-mediated signaling
pathway(s) of MB.
The ability of structurally related ligands to induce a spectrum
of receptor conformations allows for multiple signaling states
and the ability to manipulate pharmacotherapy.27,34–36 In the case
of the MB b2-AR agonists, the non-overlapping features can be in-
ferred to stabilize different conformations of the receptor.37–40 By
utilizing informed chemical modeling and phenotypic assays in
the process of compound development, it should be possible to
attenuate negative effects in addition to enhancing desired path-
ways. Our therapeutic paradigm for usage of MB agents would be
short term and low dose in order to boost mitochondrial function
to stimulate cellular/organ repair and regeneration. The pharmaco-
phore models presentedcan be utilized to develop novel com-pounds with biogenic potential that minimize the deleterious
effects sometimes associated with activation of the b2-AR.
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